JP2013501006A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501006A5
JP2013501006A5 JP2012523127A JP2012523127A JP2013501006A5 JP 2013501006 A5 JP2013501006 A5 JP 2013501006A5 JP 2012523127 A JP2012523127 A JP 2012523127A JP 2012523127 A JP2012523127 A JP 2012523127A JP 2013501006 A5 JP2013501006 A5 JP 2013501006A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501006A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044136 external-priority patent/WO2011014880A1/en
Publication of JP2013501006A publication Critical patent/JP2013501006A/ja
Publication of JP2013501006A5 publication Critical patent/JP2013501006A5/ja
Pending legal-status Critical Current

Links

JP2012523127A 2009-07-31 2010-08-02 認知機能低下の阻害剤 Pending JP2013501006A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23032609P 2009-07-31 2009-07-31
US61/230,326 2009-07-31
US30868610P 2010-02-26 2010-02-26
US61/308,686 2010-02-26
PCT/US2010/044136 WO2011014880A1 (en) 2009-07-31 2010-08-02 Inhibitors of cognitive decline

Publications (2)

Publication Number Publication Date
JP2013501006A JP2013501006A (ja) 2013-01-10
JP2013501006A5 true JP2013501006A5 (https=) 2013-09-05

Family

ID=43529740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523127A Pending JP2013501006A (ja) 2009-07-31 2010-08-02 認知機能低下の阻害剤

Country Status (12)

Country Link
US (2) US9192585B2 (https=)
EP (1) EP2458983B1 (https=)
JP (1) JP2013501006A (https=)
CN (1) CN102595884B (https=)
AU (2) AU2010278711A1 (https=)
BR (1) BR112012002246A2 (https=)
DK (1) DK2458983T3 (https=)
ES (1) ES2547730T3 (https=)
IL (1) IL217833A0 (https=)
RU (1) RU2012107457A (https=)
SG (2) SG10201506978UA (https=)
WO (1) WO2011014880A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201404913QA (en) 2009-04-09 2014-11-27 Cognition Therapeutics Inc Inhibitors of cognitive decline
RU2012107457A (ru) * 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
US9499462B2 (en) 2011-02-02 2016-11-22 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
EP2690969B1 (en) * 2011-03-29 2018-10-03 Council of Scientific & Industrial Research Process for the modification of curcuma aromatica essential oil
GB201111319D0 (en) * 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
RU2014111079A (ru) * 2011-08-25 2015-09-27 Когнишн Терапьютикс, Инк. Композиции и способы для лечения нейродегенеративного заболевания
CA2846611A1 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
EP3634394B1 (en) 2017-05-15 2025-12-24 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
DK171627B1 (da) 1983-01-31 1997-03-03 Lilly Co Eli Anvendelse af beta-phenethanolamin og farmaceutiskacceptable salte deraf samt dyrefoderpræblanding med indhold deraf
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
JP3522930B2 (ja) * 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6235731B1 (en) 1996-04-24 2001-05-22 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
US20030073681A1 (en) 2001-08-21 2003-04-17 Hauske James R. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) * 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
UA82057C2 (en) * 2001-12-14 2008-03-11 Каунсил Оф Сайентифик Энд Индастриал Рисёрч COMPOSITION basED on AR-D-turmeron and α- anD β-turmeron FOR TREATING NEUROCEREBROVASCULAR DISORDERS
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US20050032827A1 (en) 2003-06-12 2005-02-10 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
HRP20060326A2 (hr) 2004-03-12 2007-02-28 Egis Gy�gyszergy�r Nyrt. Kombinirani farmaceutski kompozit za inhibiciju pada kognitivnih funkcija
EP1752144A4 (en) * 2004-05-31 2007-07-11 Kaneka Corp AGENT FOR PREVENTING / IMPROVING LIFESTYLE DISEASES CONTAINING AN ESSENTIAL CURCUMA OIL COMPONENT
DK1794313T3 (da) 2004-06-21 2013-07-22 Proteome Sciences Plc Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1797036A1 (en) 2004-09-10 2007-06-20 UCB Pharma, S.A. Sigma receptor ligands
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
WO2006094724A2 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
KR20080041624A (ko) 2005-06-15 2008-05-13 대릭 에스. 에치. 엘. 김 베타-아밀로이드 단백질-유발 안질환의 치료 방법
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
CA2644093A1 (en) * 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. Extracts and methods comprising curcuma species
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
WO2008042755A2 (en) 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
KR20100029079A (ko) 2007-05-15 2010-03-15 헬리콘 테라퓨틱스 인코퍼레이티드 Gpr12의 저해로 인지 질환을 치료하는 방법
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
EP2138104A1 (en) 2008-06-25 2009-12-30 Vibra Tech AB Core biopsy arrangement
WO2010062260A1 (en) 2008-11-29 2010-06-03 The Thailand Research Fund Virus and target cell interaction inhibition
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
EP2408905B1 (en) 2009-03-16 2017-05-10 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
SG10201404913QA (en) 2009-04-09 2014-11-27 Cognition Therapeutics Inc Inhibitors of cognitive decline
RU2012107457A (ru) * 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
RU2014111079A (ru) 2011-08-25 2015-09-27 Когнишн Терапьютикс, Инк. Композиции и способы для лечения нейродегенеративного заболевания

Similar Documents

Publication Publication Date Title
JP2013501006A5 (https=)
JP2012523418A5 (https=)
RU2012107457A (ru) Ингибиторы ухудшения когнитивных способностей
RU2011145321A (ru) Ингибиторы снижения когнитивных способностей
RU2003130268A (ru) Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
WO2010000372A3 (en) New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
PH12014500392A1 (en) Methods of synthesis and purification of heteroaryl compounds
EA200970670A1 (ru) Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс
JP2021105002A5 (https=)
WO2010073011A3 (en) Heterocyclic compounds and their use as ampk activators
CA2456606A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2009080764A3 (en) Oral or nasal administration of compounds comprising amino acid sequences
JP2015522551A5 (https=)
JP2017537886A5 (https=)
JP2018507230A5 (https=)
JP2025111532A (ja) 5-ブロモピリジン-3-イル-3-デオキシ-3-[4-(3,4,5-トリフルオロフェニル)-1h-1,2,3-トリアゾール-1-yl]-1-チオ-アルファ-d-ガラクトピラノシド及びその結晶形を調製するための大規模方法
WO2010048452A3 (en) Polycyclic compounds and methods related thereto
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
CN114072398A (zh) 抑制tdg活性的化合物
TW200610754A (en) Vla-4 inhibitor
EP2838884A1 (en) Geranyl geranyl acetone analogs and uses thereof
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof
JP7039579B2 (ja) 抗癌剤としての4-アニリノ-キノリン化合物
CN104529724A (zh) α-细辛醇及其制备方法与应用
WO2018233483A1 (zh) 苯基喹啉酮类和黄酮类衍生物的制备和应用